Loading...
XTAEBONS
Market cap32mUSD
Dec 24, Last price  
10.00ILS
1D
2.04%
1Q
-22.48%
Jan 2017
-82.58%
Name

Bonus Biogroup Ltd

Chart & Performance

D1W1MN
XTAE:BONS chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
32.71%
Rev. gr., 5y
%
Revenues
0k
Net income
-29m
L-26.29%
-17,973,000-9,701,000-11,207,000-13,459,000-16,046,000-20,197,000-18,735,000-22,240,000-22,021,000-90,076,000-38,703,000-28,529,000
CFO
-26m
L-8.39%
-9,672,000-7,631,000-7,907,000-8,069,000-9,625,000-11,823,000-13,427,000-13,113,000-15,746,000-39,839,000-28,815,000-26,397,000

Profile

Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products include BonoFill for bone tissue regeneration in maxillofacial and orthopedic indications; and MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS, as well as other life-threatening acute inflammatory diseases. Its products in pipeline comprise bone augmentation in osteoporosis patients; novel nano-materials for drug delivery; vascularized bone grafts; and soft tissue grafts. The company was formerly known as Oceana Advanced Industries Ltd. Bonus BioGroup Ltd. was founded in 1981 and is based in Haifa, Israel.
URL
http://www.bonusbiogroup.com
IPO date
Aug 20, 1993
Employees
57
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
29,790
8,850
35,458
Unusual Expense (Income)
NOPBT
(29,790)
(8,850)
(35,458)
NOPBT Margin
Operating Taxes
7,258
(3,791)
Tax Rate
NOPAT
(29,790)
(16,108)
(31,667)
Net income
(28,529)
-26.29%
(38,703)
-57.03%
(90,076)
309.05%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,339
111,353
BB yield
-2.80%
-15.26%
Debt
Debt current
1,484
1,354
1,229
Long-term debt
20,832
22,550
23,471
Deferred revenue
Other long-term liabilities
Net debt
9,379
(29,720)
(54,761)
Cash flow
Cash from operating activities
(26,397)
(28,815)
(39,839)
CAPEX
(824)
(6,389)
(5,809)
Cash from investing activities
(14,257)
(6,293)
(6,176)
Cash from financing activities
(1,155)
2,135
113,418
FCF
(37,152)
(20,916)
(40,902)
Balance
Cash
12,937
53,624
79,453
Long term investments
8
Excess cash
12,937
53,624
79,461
Stockholders' equity
(7,078)
19,576
54,008
Invested Capital
47,541
48,765
42,772
ROIC
ROCE
EV
Common stock shares outstanding
1,167,925
621,084
579,121
Price
0.17
-13.02%
0.19
-84.76%
1.26
160.33%
Market cap
195,043
63.56%
119,248
-83.66%
729,693
282.71%
EV
204,422
89,528
674,932
EBITDA
(27,029)
(6,187)
(33,982)
EV/EBITDA
Interest
891
569
Interest/NOPBT